Loading...

PCVX VAXCYTE INC Product Launches 8-K Filing

VXCY

PCVX

VAXCYTE INC

(PCVX)

2025 8-K

Financial Results Report

Sales Agreement Signed

Financial Results Report

Stock Offering Details

Executive Changes

Earnings Report Announcement

Manufacturing Agreement

Financial Statements

Financial Statements

Financial Results

Lease Agreement

Financial Results

Earnings Reports

Appointment of Director and...

Annual Meeting of Stockholders

Earnings Reports

Earnings Reports

Underwriting Agreement

Appointment of Director

Option Grant Agreement

Earnings Reports

Agreement with Lonza for Va...

Agreement with Sutro Biopharma

Lease Agreement for Headqua...

Financial Results Announcement

Annual Meeting of Stockholders

Financial Results Announcement

Underwriting Agreement

Other Special Situation

Agreement with Lonza Ltd

Sales Agreement Amendment

Earnings Reports

External Links:

On March 31, 2025, Vaxcyte, Inc. announced positive results from its Phase 2 study of VAX-24, a vaccine for invasive pneumococcal disease, and mentioned ongoing development of VAX-XL.

AI Assistant

VAXCYTE INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.